Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes
Cardiac hypertrophy impairs Ca 2+ handling in the sarcoplasmic reticulum, thereby impairing cardiac contraction. To identify the mechanisms underlying impaired Ca 2+ release from the sarcoplasmic reticulum in hypertrophic cardiomyocytes, we assessed Ca 2+-dependent signaling and the phosphorylation...
Gespeichert in:
Veröffentlicht in: | Biochemical pharmacology 2007-12, Vol.74 (12), p.1727-1737 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1737 |
---|---|
container_issue | 12 |
container_start_page | 1727 |
container_title | Biochemical pharmacology |
container_volume | 74 |
creator | Lu, Ying-Mei Shioda, Norifumi Han, Feng Moriguchi, Shigeki Kasahara, Jiro Shirasaki, Yasufumi Qin, Zheng-Hong Fukunaga, Kohji |
description | Cardiac hypertrophy impairs Ca
2+ handling in the sarcoplasmic reticulum, thereby impairing cardiac contraction. To identify the mechanisms underlying impaired Ca
2+ release from the sarcoplasmic reticulum in hypertrophic cardiomyocytes, we assessed Ca
2+-dependent signaling and the phosphorylation of phospholamban, which regulates Ca
2+ uptake during myocardial relaxation and is in turn regulated by Ca
2+/calmodulin-dependent protein kinase II (CaMKII) and calcineurin. In cultured rat cardiomyocytes, treatment with endothelin-1, angiotensin II, and phenylephrine-induced hypertrophy and increased CaMKII autophosphorylation and calcineurin expression. The calcineurin level reached its maximum at 72
h and remained elevated for at least 96
h after endothelin-1 or angiotensin II treatment. By contrast, CaMKII autophosphorylation, phospholamban phosphorylation, and caffeine-induced Ca
2+ mobilization all peaked 48
h after these treatments. By 96
h after treatment, CaMKII autophosphorylation and phospholamban phosphorylation had returned to baseline, and caffeine-induced Ca
2+ mobilization was impaired relative to baseline. A similar biphasic change was observed in dystrophin levels in endothelin-1-induced hypertrophic cardiomyocytes, and treatment with the novel CaM antagonists DY-9760e and DY-9836 significantly inhibited the hypertrophy-induced dystrophin breakdown. Taken together, the abnormal Ca
2+ regulation in cardiomyocytes following hypertrophy is in part mediated by an imbalance in calcineurin and CaMKII activities, which leads to abnormal phospholamban activity. |
doi_str_mv | 10.1016/j.bcp.2007.08.022 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19631188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006295207005734</els_id><sourcerecordid>19631188</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-e488108ed4eddaedb0c48439ce6b6956d663fe6145d56ba6705ebcdde3992b3f3</originalsourceid><addsrcrecordid>eNp9kTtP5DAURi20CGaBH0CzcrN0CXYejiMqNILdkUA0UFt-3Ig75LV2ApqWX45HE4luK9v6zndlHxNyyVnKGRfX29TYMc0Yq1ImU5ZlR2TFZZUnWS3kD7JijIm4L7NT8jOE7f4oBT8hp7ySUhasWpHPTWd0q3sL1MD0AdDTtX6kb9jrAHSzobp31OrWYg-zx55qO-E7TgiBYjdq9CHGTQMxT7B3s4WFnzvqoYX9mFh73Y3gJz-Mr2hj7h0O3W6wuwnCOTludBvgYlnPyMv93fP6b_Lw9Gezvn1IbFHJKYFCSs4kuAKc0-AMs4Us8tqCMKIuhRMib0DwonSlMFpUrARjnYO8rjOTN_kZuTrMHf3wb4YwqQ6DhTa-HoY5KF6LnHMpI8gPoPVDCB4aNXrstN8pztRevNqqKF7txSsmVRQfO7-W4bPpwH03FtMR-L0AOkQ_jY_OMXxztRR5WdSRuzlwEFW8I3gVLEL8H4ce7KTcgP-5xhdj2aPJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19631188</pqid></control><display><type>article</type><title>Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Lu, Ying-Mei ; Shioda, Norifumi ; Han, Feng ; Moriguchi, Shigeki ; Kasahara, Jiro ; Shirasaki, Yasufumi ; Qin, Zheng-Hong ; Fukunaga, Kohji</creator><creatorcontrib>Lu, Ying-Mei ; Shioda, Norifumi ; Han, Feng ; Moriguchi, Shigeki ; Kasahara, Jiro ; Shirasaki, Yasufumi ; Qin, Zheng-Hong ; Fukunaga, Kohji</creatorcontrib><description>Cardiac hypertrophy impairs Ca
2+ handling in the sarcoplasmic reticulum, thereby impairing cardiac contraction. To identify the mechanisms underlying impaired Ca
2+ release from the sarcoplasmic reticulum in hypertrophic cardiomyocytes, we assessed Ca
2+-dependent signaling and the phosphorylation of phospholamban, which regulates Ca
2+ uptake during myocardial relaxation and is in turn regulated by Ca
2+/calmodulin-dependent protein kinase II (CaMKII) and calcineurin. In cultured rat cardiomyocytes, treatment with endothelin-1, angiotensin II, and phenylephrine-induced hypertrophy and increased CaMKII autophosphorylation and calcineurin expression. The calcineurin level reached its maximum at 72
h and remained elevated for at least 96
h after endothelin-1 or angiotensin II treatment. By contrast, CaMKII autophosphorylation, phospholamban phosphorylation, and caffeine-induced Ca
2+ mobilization all peaked 48
h after these treatments. By 96
h after treatment, CaMKII autophosphorylation and phospholamban phosphorylation had returned to baseline, and caffeine-induced Ca
2+ mobilization was impaired relative to baseline. A similar biphasic change was observed in dystrophin levels in endothelin-1-induced hypertrophic cardiomyocytes, and treatment with the novel CaM antagonists DY-9760e and DY-9836 significantly inhibited the hypertrophy-induced dystrophin breakdown. Taken together, the abnormal Ca
2+ regulation in cardiomyocytes following hypertrophy is in part mediated by an imbalance in calcineurin and CaMKII activities, which leads to abnormal phospholamban activity.</description><identifier>ISSN: 0006-2952</identifier><identifier>EISSN: 1873-2968</identifier><identifier>DOI: 10.1016/j.bcp.2007.08.022</identifier><identifier>PMID: 17888407</identifier><identifier>CODEN: BCPCA6</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Angiotensin II - pharmacology ; Animals ; Biological and medical sciences ; Calcineurin ; Calcineurin - metabolism ; Calcium - metabolism ; Calcium-Binding Proteins - metabolism ; Calcium-Calmodulin-Dependent Protein Kinase Type 2 - metabolism ; CaMKII ; Cardiomegaly - chemically induced ; Cardiomegaly - enzymology ; Cardiomegaly - metabolism ; Cardiomyocyte ; Cells, Cultured ; DY-9760e ; Endothelin-1 - pharmacology ; Hypertrophy ; Immunohistochemistry ; Indazoles - pharmacology ; Medical sciences ; Pharmacology. Drug treatments ; Phenylephrine - pharmacology ; Phospholamban ; Phosphorylation ; Rats ; Rats, Wistar</subject><ispartof>Biochemical pharmacology, 2007-12, Vol.74 (12), p.1727-1737</ispartof><rights>2007 Elsevier Inc.</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-e488108ed4eddaedb0c48439ce6b6956d663fe6145d56ba6705ebcdde3992b3f3</citedby><cites>FETCH-LOGICAL-c478t-e488108ed4eddaedb0c48439ce6b6956d663fe6145d56ba6705ebcdde3992b3f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bcp.2007.08.022$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19863549$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17888407$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lu, Ying-Mei</creatorcontrib><creatorcontrib>Shioda, Norifumi</creatorcontrib><creatorcontrib>Han, Feng</creatorcontrib><creatorcontrib>Moriguchi, Shigeki</creatorcontrib><creatorcontrib>Kasahara, Jiro</creatorcontrib><creatorcontrib>Shirasaki, Yasufumi</creatorcontrib><creatorcontrib>Qin, Zheng-Hong</creatorcontrib><creatorcontrib>Fukunaga, Kohji</creatorcontrib><title>Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes</title><title>Biochemical pharmacology</title><addtitle>Biochem Pharmacol</addtitle><description>Cardiac hypertrophy impairs Ca
2+ handling in the sarcoplasmic reticulum, thereby impairing cardiac contraction. To identify the mechanisms underlying impaired Ca
2+ release from the sarcoplasmic reticulum in hypertrophic cardiomyocytes, we assessed Ca
2+-dependent signaling and the phosphorylation of phospholamban, which regulates Ca
2+ uptake during myocardial relaxation and is in turn regulated by Ca
2+/calmodulin-dependent protein kinase II (CaMKII) and calcineurin. In cultured rat cardiomyocytes, treatment with endothelin-1, angiotensin II, and phenylephrine-induced hypertrophy and increased CaMKII autophosphorylation and calcineurin expression. The calcineurin level reached its maximum at 72
h and remained elevated for at least 96
h after endothelin-1 or angiotensin II treatment. By contrast, CaMKII autophosphorylation, phospholamban phosphorylation, and caffeine-induced Ca
2+ mobilization all peaked 48
h after these treatments. By 96
h after treatment, CaMKII autophosphorylation and phospholamban phosphorylation had returned to baseline, and caffeine-induced Ca
2+ mobilization was impaired relative to baseline. A similar biphasic change was observed in dystrophin levels in endothelin-1-induced hypertrophic cardiomyocytes, and treatment with the novel CaM antagonists DY-9760e and DY-9836 significantly inhibited the hypertrophy-induced dystrophin breakdown. Taken together, the abnormal Ca
2+ regulation in cardiomyocytes following hypertrophy is in part mediated by an imbalance in calcineurin and CaMKII activities, which leads to abnormal phospholamban activity.</description><subject>Angiotensin II - pharmacology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Calcineurin</subject><subject>Calcineurin - metabolism</subject><subject>Calcium - metabolism</subject><subject>Calcium-Binding Proteins - metabolism</subject><subject>Calcium-Calmodulin-Dependent Protein Kinase Type 2 - metabolism</subject><subject>CaMKII</subject><subject>Cardiomegaly - chemically induced</subject><subject>Cardiomegaly - enzymology</subject><subject>Cardiomegaly - metabolism</subject><subject>Cardiomyocyte</subject><subject>Cells, Cultured</subject><subject>DY-9760e</subject><subject>Endothelin-1 - pharmacology</subject><subject>Hypertrophy</subject><subject>Immunohistochemistry</subject><subject>Indazoles - pharmacology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenylephrine - pharmacology</subject><subject>Phospholamban</subject><subject>Phosphorylation</subject><subject>Rats</subject><subject>Rats, Wistar</subject><issn>0006-2952</issn><issn>1873-2968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kTtP5DAURi20CGaBH0CzcrN0CXYejiMqNILdkUA0UFt-3Ig75LV2ApqWX45HE4luK9v6zndlHxNyyVnKGRfX29TYMc0Yq1ImU5ZlR2TFZZUnWS3kD7JijIm4L7NT8jOE7f4oBT8hp7ySUhasWpHPTWd0q3sL1MD0AdDTtX6kb9jrAHSzobp31OrWYg-zx55qO-E7TgiBYjdq9CHGTQMxT7B3s4WFnzvqoYX9mFh73Y3gJz-Mr2hj7h0O3W6wuwnCOTludBvgYlnPyMv93fP6b_Lw9Gezvn1IbFHJKYFCSs4kuAKc0-AMs4Us8tqCMKIuhRMib0DwonSlMFpUrARjnYO8rjOTN_kZuTrMHf3wb4YwqQ6DhTa-HoY5KF6LnHMpI8gPoPVDCB4aNXrstN8pztRevNqqKF7txSsmVRQfO7-W4bPpwH03FtMR-L0AOkQ_jY_OMXxztRR5WdSRuzlwEFW8I3gVLEL8H4ce7KTcgP-5xhdj2aPJ</recordid><startdate>20071215</startdate><enddate>20071215</enddate><creator>Lu, Ying-Mei</creator><creator>Shioda, Norifumi</creator><creator>Han, Feng</creator><creator>Moriguchi, Shigeki</creator><creator>Kasahara, Jiro</creator><creator>Shirasaki, Yasufumi</creator><creator>Qin, Zheng-Hong</creator><creator>Fukunaga, Kohji</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20071215</creationdate><title>Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes</title><author>Lu, Ying-Mei ; Shioda, Norifumi ; Han, Feng ; Moriguchi, Shigeki ; Kasahara, Jiro ; Shirasaki, Yasufumi ; Qin, Zheng-Hong ; Fukunaga, Kohji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-e488108ed4eddaedb0c48439ce6b6956d663fe6145d56ba6705ebcdde3992b3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Angiotensin II - pharmacology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Calcineurin</topic><topic>Calcineurin - metabolism</topic><topic>Calcium - metabolism</topic><topic>Calcium-Binding Proteins - metabolism</topic><topic>Calcium-Calmodulin-Dependent Protein Kinase Type 2 - metabolism</topic><topic>CaMKII</topic><topic>Cardiomegaly - chemically induced</topic><topic>Cardiomegaly - enzymology</topic><topic>Cardiomegaly - metabolism</topic><topic>Cardiomyocyte</topic><topic>Cells, Cultured</topic><topic>DY-9760e</topic><topic>Endothelin-1 - pharmacology</topic><topic>Hypertrophy</topic><topic>Immunohistochemistry</topic><topic>Indazoles - pharmacology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenylephrine - pharmacology</topic><topic>Phospholamban</topic><topic>Phosphorylation</topic><topic>Rats</topic><topic>Rats, Wistar</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Ying-Mei</creatorcontrib><creatorcontrib>Shioda, Norifumi</creatorcontrib><creatorcontrib>Han, Feng</creatorcontrib><creatorcontrib>Moriguchi, Shigeki</creatorcontrib><creatorcontrib>Kasahara, Jiro</creatorcontrib><creatorcontrib>Shirasaki, Yasufumi</creatorcontrib><creatorcontrib>Qin, Zheng-Hong</creatorcontrib><creatorcontrib>Fukunaga, Kohji</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Biochemical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Ying-Mei</au><au>Shioda, Norifumi</au><au>Han, Feng</au><au>Moriguchi, Shigeki</au><au>Kasahara, Jiro</au><au>Shirasaki, Yasufumi</au><au>Qin, Zheng-Hong</au><au>Fukunaga, Kohji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes</atitle><jtitle>Biochemical pharmacology</jtitle><addtitle>Biochem Pharmacol</addtitle><date>2007-12-15</date><risdate>2007</risdate><volume>74</volume><issue>12</issue><spage>1727</spage><epage>1737</epage><pages>1727-1737</pages><issn>0006-2952</issn><eissn>1873-2968</eissn><coden>BCPCA6</coden><abstract>Cardiac hypertrophy impairs Ca
2+ handling in the sarcoplasmic reticulum, thereby impairing cardiac contraction. To identify the mechanisms underlying impaired Ca
2+ release from the sarcoplasmic reticulum in hypertrophic cardiomyocytes, we assessed Ca
2+-dependent signaling and the phosphorylation of phospholamban, which regulates Ca
2+ uptake during myocardial relaxation and is in turn regulated by Ca
2+/calmodulin-dependent protein kinase II (CaMKII) and calcineurin. In cultured rat cardiomyocytes, treatment with endothelin-1, angiotensin II, and phenylephrine-induced hypertrophy and increased CaMKII autophosphorylation and calcineurin expression. The calcineurin level reached its maximum at 72
h and remained elevated for at least 96
h after endothelin-1 or angiotensin II treatment. By contrast, CaMKII autophosphorylation, phospholamban phosphorylation, and caffeine-induced Ca
2+ mobilization all peaked 48
h after these treatments. By 96
h after treatment, CaMKII autophosphorylation and phospholamban phosphorylation had returned to baseline, and caffeine-induced Ca
2+ mobilization was impaired relative to baseline. A similar biphasic change was observed in dystrophin levels in endothelin-1-induced hypertrophic cardiomyocytes, and treatment with the novel CaM antagonists DY-9760e and DY-9836 significantly inhibited the hypertrophy-induced dystrophin breakdown. Taken together, the abnormal Ca
2+ regulation in cardiomyocytes following hypertrophy is in part mediated by an imbalance in calcineurin and CaMKII activities, which leads to abnormal phospholamban activity.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>17888407</pmid><doi>10.1016/j.bcp.2007.08.022</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-2952 |
ispartof | Biochemical pharmacology, 2007-12, Vol.74 (12), p.1727-1737 |
issn | 0006-2952 1873-2968 |
language | eng |
recordid | cdi_proquest_miscellaneous_19631188 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Angiotensin II - pharmacology Animals Biological and medical sciences Calcineurin Calcineurin - metabolism Calcium - metabolism Calcium-Binding Proteins - metabolism Calcium-Calmodulin-Dependent Protein Kinase Type 2 - metabolism CaMKII Cardiomegaly - chemically induced Cardiomegaly - enzymology Cardiomegaly - metabolism Cardiomyocyte Cells, Cultured DY-9760e Endothelin-1 - pharmacology Hypertrophy Immunohistochemistry Indazoles - pharmacology Medical sciences Pharmacology. Drug treatments Phenylephrine - pharmacology Phospholamban Phosphorylation Rats Rats, Wistar |
title | Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T23%3A31%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Imbalance%20between%20CaM%20kinase%20II%20and%20calcineurin%20activities%20impairs%20caffeine-induced%20calcium%20release%20in%20hypertrophic%20cardiomyocytes&rft.jtitle=Biochemical%20pharmacology&rft.au=Lu,%20Ying-Mei&rft.date=2007-12-15&rft.volume=74&rft.issue=12&rft.spage=1727&rft.epage=1737&rft.pages=1727-1737&rft.issn=0006-2952&rft.eissn=1873-2968&rft.coden=BCPCA6&rft_id=info:doi/10.1016/j.bcp.2007.08.022&rft_dat=%3Cproquest_cross%3E19631188%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19631188&rft_id=info:pmid/17888407&rft_els_id=S0006295207005734&rfr_iscdi=true |